Brought to you by 
Pernix pays $101mm for generics firm Cypress and its branded drug unit Hawthorn
07 Feb 2014
Executive Summary
Calling the deal its most significant acquisition since its 1996 inception, Pernix Therapeutics Holdings Inc. (brand, generic, and OTC pharmaceuticals) has paid $91mm up front and pledged $10mm in earn-outs for private generic firm Cypress Pharmaceutical Inc. The transaction, which Pernix is financing via a $60mm credit facility from MidCap, also includes Cypress’ branded drug division Hawthorn Pharmaceuticals Inc.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pernix pays $101mm for generics firm Cypress and its branded drug unit Hawthorn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice